ClinicalTrials.gg
Status unknownNCT06024447Updated May 17, 2024

Impact of Subgingival Instrumentation on Masticatory Performance and Psychological Distress

An interventional study of Subgingival Instrumentation in Periodontitis, sponsored by Postgraduate Institute of Dental Sciences Rohtak. Status unknown at 1 site in India. Open to participants aged 30 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-05-17.

Sponsored by Postgraduate Institute of Dental Sciences Rohtak · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified May 2024), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
92
Allocation
Not applicable
Ages
30 Years to 50 Years
Sex
All
01

Study summary

Patients of Stage III and Stage IV Periodontitis will be assessed for masticatory dysfunction and psychological distress. Subgingival Instrumentation will be done for treating periodontitis. Patients will be re-evaluated after 2 and 3 months in order to assess any change in masticatory dysfunction and psychological distress by improved periodontal health.

Read the detailed description

Literature reveals that there occurs masticatory dysfunction in patients with Stage III and IV Periodontitis. It has been hypothesized that masticatory dysfunction along with halitosis and aesthetics of the patient can have an effect on the psychological distress in a chronic state.

Patients of Stage III and Stage IV Periodontitis with the following criteria will be included :

  1. Adult patients with age group 30-50 years diagnosed with stage III/IV generalized periodontitis.
  2. Presence of minimum 20 teeth (Eichner group A1, A2, A3) excluding third molars.

Exclusion Criteria: Patients with

  1. Systemic diseases that may affect periodontal disease progression or outcome of treatment (diabetes, autoimmune diseases)
  2. Systemic diseases that may affect masticatory ability of the patient (sarcopenia, TMJ disorders, Xerostomia, Acute Pulpitis)
  3. History of periodontal treatment within the 6 months
  4. Patients wearing orthodontic appliances
  5. Diagnosed psychiatric disorder
  6. History of antibiotic use within the previous 3 months
  7. History of use of Steroid, immunosuppressive and psychiatric drugs
  8. Pregnant and lactating women
  9. Smoking or substance abuse
  10. History of Menopause

Periodontal clinical parameters:

Plaque Index, Gingival Index, Bleeding on Probing, Probing Pocket Depth, Clinical Attachment Level, Mobility Psychological Parameters: Hospital Anxiety and Depression Scale -14 and Depression Anxiety and Stress Scale -21 Quality of Masticatory Dysfunction Questionnaire and Objective evaluation of Masticatory Performance by mixing ability of Hubba Bubba chewing gum.

The sample of 84 patients consisting of 42 cases and 42 controls. The patients will be re-evaluated at 2 and 3 months follow up for clinical periodontal parameters, masticatory performance and psychological distress.

02

Conditions studied

  • Periodontitis

Browse trials for

03

In context

Periodontitis

1,664 studies on the registry are indexed under Periodontitis; 328 are open to participants now.

This study's planned enrollment of 92 is above the median of 45 across 1,206 interventional studies indexed under Periodontitis.

Browse Periodontitis studies →

Lead sponsor

Postgraduate Institute of Dental Sciences Rohtak is the lead sponsor of 213 studies on the registry; 72 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
30 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients with age group 30-50 years diagnosed with stage III/IV generalized periodontitis.
  • Presence of minimum 20 teeth (Eichner group A1, A2, A3) excluding third molars.

Exclusion criteria

Exclusion Criteria:

  • Systemic diseases that may affect periodontal disease progression or outcome of treatment (diabetes, autoimmune diseases)
  • Systemic diseases that may affect masticatory ability of the patient (sarcopenia, TMJ disorders, Xerostomia, Acute Pulpitis)
  • Periodontal treatment within the 6 months
  • Patients wearing orthodontic appliances
  • Any diagnosed psychiatric disorder
  • Antibiotic use within the previous 3 months
  • Steroid, immunosuppressive and psychiatric drug use
  • Pregnant and lactating women
  • History of menopause
  • Smoking or substance abuse
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
92 participants (estimated)

Study arms

  • Other
    Stage III and Stage IV Periodontitis

    Subgingival Instrumentation will be performed in patients with Stage III and Stage IV periodontitis.

    Procedure: Subgingival Instrumentation

Interventions

  • ProcedureSubgingival Instrumentation

    Subgingival Instrumentation will be performed in patients with Stage III and IV periodontitis.

06

What researchers measure

Primary outcomes

  1. Masticatory performance

    Objective Masticatory Performance will be evaluated using colour mixing ability of a chewing gum, through optoelectronic analysis using a software. Subjective masticatory performance will be calculated using The Quality of Masticatory Function questionnaire which consists of 29 questions related to frequency and difficulty of chewing different types of foods in the previous 2 weeks.

    Time frame: Baseline, 2 months, 3 months

  2. Hospital Anxiety and Depression Scale 14

    The HADS constitutes 14 items grouped into two subscales: "anxiety subscale" (HADS-A), as well as "depression subscale" (HADS-D). The responses to the items are graded from 0 (absence of manifestations) to 3 (severe manifestations). Scores are summated to yield the total score, and greater scores indicate more severe anxiety, as well as depressive indications. DASS-21 measures emotional distress in three subcategories of depression (e.g., loss of self-esteem/incentives and depressed mood), anxiety (e.g., fear and anticipation of negative events), and stress (e.g., persistent state of over arousal and low frustration tolerance). It is a self-reporting questionnaire with 21 items (seven items for each category) based on a four-point rating scale. Higher score represents more severe emotional distress.

    Time frame: Baseline, 2 months, 3 months

  3. Depression Anxiety and Stress Scale 21

    DASS-21 measures emotional distress in three subcategories of depression (e.g., loss of self-esteem/incentives and depressed mood), anxiety (e.g., fear and anticipation of negative events), and stress (e.g., persistent state of over arousal and low frustration tolerance). It is a self-reporting questionnaire with 21 items (seven items for each category) based on a four-point rating scale. Higher score represents more severe emotional distress.

    Time frame: Baseline, 2 months, 3 months

Secondary outcomes

  1. Pocket Probing Depth

    The probe UNC 15 will be inserted with a firm, gentle pressure to the bottom of the pocket and maintained parallel to the vertical axis of the tooth. Measurements will be noted at 6 sites of involved tooth - mesio-buccal, mid-buccal, disto-buccal, mesio-lingual, mid-lingual, disto-lingual.

    Time frame: Baseline, 2 months, 3 months

  2. Clinical attachment level

    Clinical Attachment Level will be measured as a distance between from the base of the clinical pocket and the cemento-enamel junction (CEJ). Measurements will be made at 6 sites of involved tooth.

    Time frame: Baseline, 2 months, 3 months

07

Study locations

1 of 1 sites recruiting
  • Post Graduate Institute of Dental Sciences
    Rohtak, Haryana 124001, India
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 17, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06024447
Responsible party
Sponsor
First posted
Sep 6, 2023
Start date
Sep 15, 2023
Primary completion
Sep 15, 2024 (estimated)
Completion
Oct 15, 2024 (estimated)
Last update
May 17, 2024

Study contacts

Sanjay Tewari, MDS
Contact
principalpgids@yahoo.in
91-1262-283876
Janvi Janvi, BDS
principal investigator · PGIDS Rohtak

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion